Exscientia Sets IPO at 13.1 Million ADSs; Sees Pricing at $20-$22 Each

Dow Jones2021-09-27

Exscientia PLC on Monday said it plans to sell nearly 13.1 million American depositary shares at between $20 and $22 apiece in its initial public offering.

At the $21 midpoint of that range, the Oxford, U.K., clinical-stage pharmatech company said it expects net proceeds of about $249.2 million, or roughly $287.6 million if the underwriters exercise an option to buy an additional 1.96 million ADSs.

Exscientia said it also expects to net about $151.3 million from concurrent private placements of $125 million with an affiliate of SoftBank Group Corp. and $35 million with the Bill & Melinda Gates Foundation.

Exscientia, which is using artificial intelligence to design patient-based drugs, said it believes the proceeds from the IPO and private placements, coupled with its existing resources, will be sufficient to fund its operations and capital-spending needs for at least a year.

Each Exscientia represents one ordinary share. In a filing with the U.S. Securities and Exchange Commission, Exscientia said it would have about 119.9 million shares outstanding after the IPO and private placements, assuming exercise of the overallotment option, for a market capitalization topping $2.5 billion at the $21-a-share pricing midpoint.

Exscientia said it has applied to list its ADSs on the Nasdaq Global Select Market under the symbol EXAI.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

发表看法
8